Clinical implications for post-ACS patients

27 August 2018 (18:55 - 19:10)

Organised by:

Video

Sign in to view the resources

Slides

About the speaker

Doctor Shaun Goodman

St. Michael's Hospital, Toronto (Canada)

6 More presentations in this session

Presentation thumbnail

Welcome and introduction - Highlights from the latest ODYSSEY OUTCOMES data

Professor A. Zeiher (Frankfurt, DE)

Presentation thumbnail

Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: post- ACS patients with elevated atherogenic lipid levels

Professor P. Steg (Paris, FR)

Presentation thumbnail

Learnings from the latest PCSK9i results and and profiles of patients who may benefit the most: efficacy and safety of alirocumab in ODYSSEY OUTCOMES patients with diabetes

Professor K. Ray (London, GB)

Presentation thumbnail

Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: a comprehensive review of the latest lipid lowering therapies outcomes data

Professor C. Cannon (Boston, US)

Presentation thumbnail

Roundtable: learnings in practice

Professor P. Steg (Paris, FR) Professor A. Zeiher (Frankfurt, DE)

Access the full session

Session thumbnail

Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data

The Event

ESC Congress 2018

27 August 2018 18:55 CET

You may be interested in

Webinar

LDL-C reduction postACS: strike early and strike strong

15 November 2021

Congress Session

Young Investigator Awards Session in Thrombosis

25 August 2023

ESC TV Today

Episode 17: Coronary sinus reducer - Best strategies to reach LDL cholesterol goals

5 June 2025

Congress Session

State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?

14 March 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources